Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Pediatr Blood Cancer. 2014 Sep 24;62(1):45–51. doi: 10.1002/pbc.25229

Figure 1.

Figure 1

Radiographic changes to the distal femoral growth plate during anti-angiogenic therapy using multi-targeted tyrosine kinase inhibitors sunitinib and pazopanib directed against VEGF signaling pathways. (A, B) 8 yo patient being treated with pazopanib‥ (C,D) 7 yo patient being treated with sunitinib. Comparing baseline (A,C) to post-treatment course 4 (B) and course 15 (D) radiographs, respectively, both patients show unequivocal growth plate widening (arrows) while on treatment with VEGF-targeted anti-angiogenic agents. Similar findings were seen in three additional patients treated with pazopanib (Figs. 2–4, and data not shown).